1. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

  2. Beyond the estrogen receptor: In search of predictive biomarkers for low-grade serous ovarian cancer

  3. Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies

  4. Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis

  5. Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma

  6. Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial

  7. Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery

  8. Interobserver reproducibility in assessing eosinophilic cells in ovarian serous borderline tumors to predict BRAF mutational status

  9. Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma

  10. Low-grade serous ovarian cancer: expert consensus report on the state of the science

  11. Molecular characteristics and clinical behaviour of epithelial ovarian cancers

  12. Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

  13. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  14. Novel therapeutics in low-grade serous ovarian cancer

  15. Ovarian combined serous borderline tumor/low-grade serous carcinoma and mesonephric-like lesion: report of 2 cases with new observations

  16. Risk of non-ovarian cancer in a nationwide-based study of nearly 5,000 women with borderline ovarian tumors in Denmark

  17. Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas

  18. The highs and lows of serous ovarian cancer

  19. The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches

  20. Update on new treatments for rare ovarian tumours

  21. Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas

  22. Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome

Previous

2024
Next

2022